Coagulation Factor V (F5)

[Edit]

FV; FVL; PCCF; Proaccelerin; Labile Factor; Factor V Leiden; Accelerator Globulin; Activated protein C cofactor; Proaccelerin, labile factor

Coagulation Factor V (F5)

Factor V is an essential cofactor of the blood coagulation cascade. This factor circulates in plasma, and is converted to the active form by the release of the activation peptide by thrombin during coagulation. This generates a heavy chain and a light chain which are held together by calcium ions. The activated protein is a cofactor that participates with activated coagulation factor X to activate prothrombin to thrombin. 

Factor 5 is a protein of the coagulation system, rarely referred to as proaccelerin or labile factor. In contrast to most other coagulation factors, it is not enzymatically active but functions as a cofactor. Deficiency leads to predisposition for hemorrhage, while some mutations (most notably factor V Leiden) predispose for thrombosis.

Organism species: Homo sapiens (Human)

CATALOG NO.PRODUCT NAMEAPPLICATIONS
ProteinsRPA675Hu01Recombinant Coagulation Factor V (F5)SDS-PAGE; WB; ELISA; IP; CoIP; Purification; Amine Reactive Labeling.
RPA675Hu02Recombinant Coagulation Factor V (F5)SDS-PAGE; WB; ELISA; IP.
RPA675Hu03Recombinant Coagulation Factor V (F5)SDS-PAGE; WB; ELISA; IP.
AntibodiesPAA675Hu01Polyclonal Antibody to Coagulation Factor V (F5)WB, ICC, IHC-P, IHC-F, ELISA
MAA675Hu22Monoclonal Antibody to Coagulation Factor V (F5)WB, ICC, IHC-P, IHC-F, ELISA
PAA675Hu02Polyclonal Antibody to Coagulation Factor V (F5)WB; ICC; IHC-P; IHC-F; ELISA; IP; IF; FCM.
LAA675Hu81FITC-Linked Polyclonal Antibody to Coagulation Factor V (F5)IHC;ICC;IF;WB
LAA675Hu71Biotin-Linked Polyclonal Antibody to Coagulation Factor V (F5)IHC;WB;ELISA
PAA675Hu03Polyclonal Antibody to Coagulation Factor V (F5)WB, ICC, IHC-P, IHC-F, ELISA
Assay KitsSEA675HuELISA Kit for Coagulation Factor V (F5)Enzyme-linked immunosorbent assay for Antigen Detection

Organism species: Mus musculus (Mouse)

CATALOG NO.PRODUCT NAMEAPPLICATIONS
ProteinsRPA675Mu01Recombinant Coagulation Factor V (F5)SDS-PAGE; WB; ELISA; IP.
RPA675Mu02Recombinant Coagulation Factor V (F5)SDS-PAGE; WB; ELISA; IP.
RPA675Mu03Recombinant Coagulation Factor V (F5)SDS-PAGE; WB; ELISA; IP.
AntibodiesPAA675Mu01Polyclonal Antibody to Coagulation Factor V (F5)WB, ICC, IHC-P, IHC-F, ELISA
PAA675Mu02Polyclonal Antibody to Coagulation Factor V (F5)WB, ICC, IHC-P, IHC-F, ELISA
PAA675Mu03Polyclonal Antibody to Coagulation Factor V (F5)WB, ICC, IHC-P, IHC-F, ELISA
Assay KitsSEA675MuELISA Kit for Coagulation Factor V (F5)Enzyme-linked immunosorbent assay for Antigen Detection

Organism species: Rattus norvegicus (Rat)

CATALOG NO.PRODUCT NAMEAPPLICATIONS
ProteinsRPA675Ra01Recombinant Coagulation Factor V (F5)SDS-PAGE; WB; ELISA; IP.
AntibodiesPAA675Ra01Polyclonal Antibody to Coagulation Factor V (F5)WB, ICC, IHC-P, IHC-F, ELISA
MAA675Ra21Monoclonal Antibody to Coagulation Factor V (F5)WB, ICC, IHC-P, IHC-F, ELISA
Assay KitsSEA675RaELISA Kit for Coagulation Factor V (F5)Enzyme-linked immunosorbent assay for Antigen Detection

Organism species: Sus scrofa; Porcine (Pig)

CATALOG NO.PRODUCT NAMEAPPLICATIONS
ProteinsRPA675Po01Recombinant Coagulation Factor V (F5)SDS-PAGE; WB; ELISA; IP; CoIP; Purification; Amine Reactive Labeling.
AntibodiesPAA675Po01Polyclonal Antibody to Coagulation Factor V (F5)WB, ICC, IHC-P, IHC-F, ELISA
LAA675Po71Biotin-Linked Polyclonal Antibody to Coagulation Factor V (F5)IHC;WB;ELISA
MAA675Po21Monoclonal Antibody to Coagulation Factor V (F5)WB, ICC, IHC-P, IHC-F, ELISA
Assay Kitsn/aCLIA Kit for Coagulation Factor V (F5)CLIA Kit Customized Service Offer
n/aELISA Kit for Coagulation Factor V (F5)ELISA Kit Customized Service Offer
  1. "Complete cDNA and derived amino acid sequence of human factor V."Proc. Natl. Acad. Sci. U.S.A. 84:4846-4850(1987) [PubMed] [Europe PMC] [Abstract]
  2. "Structure of the gene for human coagulation factor V."Biochemistry 31:3777-3785(1992) [PubMed] [Europe PMC] [Abstract]
  3. "The DNA sequence and biological annotation of human chromosome 1." Nature 441:315-321(2006) [PubMed] [Europe PMC] [Abstract]
  4. "Complete sequencing and characterization of 21,243 full-length human cDNAs." Nat. Genet. 36:40-45(2004) [PubMed] [Europe PMC] [Abstract]
  5. "Cloning of cDNAs coding for the heavy chain region and connecting region of human factor V, a blood coagulation factor with four types of internal repeats."Biochemistry 26:6508-6514(1987) [PubMed] [Europe PMC] [Abstract]
  6. "Studies on hereditary deficiency of coagulation factor V."Zhonghua Xue Ye Xue Za Zhi 22:453-456(2001) [PubMed] [Europe PMC] [Abstract]
  7. "Cloning of a cDNA coding for human factor V, a blood coagulation factor homologous to factor VIII and ceruloplasmin."Proc. Natl. Acad. Sci. U.S.A. 83:6800-6804(1986) [PubMed] [Europe PMC] [Abstract]
  8. "The serine protease cofactor factor V is synthesized by lymphocytes."J. Immunol. 150:2992-3001(1993) [PubMed] [Europe PMC] [Abstract]
  9. "Mechanism of inhibition of activated protein C by protein C inhibitor."J. Biochem. 95:187-195(1984) [PubMed] [Europe PMC] [Abstract]
  10. "Coagulation Factor V contains copper ion."J. Biol. Chem. 259:12949-12951(1984) [PubMed] [Europe PMC] [Abstract]
  11. "Inactivation of human plasma kallikrein and factor XIa by protein C inhibitor."Biochemistry 27:4231-4237(1988) [PubMed] [Europe PMC] [Abstract]
  12. "Posttranslational sulfation of factor V is required for efficient thrombin cleavage and activation and for full procoagulant activity."Biochemistry 33:6952-6959(1994) [PubMed] [Europe PMC] [Abstract]
  13. "Sulfation of tyrosine residues in coagulation factor V."Blood 76:946-952(1990) [PubMed] [Europe PMC] [Abstract]
  14. "The mechanism of inactivation of human factor V and human factor Va by activated protein C."J. Biol. Chem. 269:31869-31880(1994) [PubMed] [Europe PMC] [Abstract]
  15. "Characterization of semenogelin II and its molecular interaction with prostate-specific antigen and protein C inhibitor."Eur. J. Biochem. 238:88-96(1996) [PubMed] [Europe PMC] [Abstract]
  16. "Protein C inhibitor secreted from activated platelets efficiently inhibits activated protein C on phosphatidylethanolamine of platelet membrane and microvesicles."J. Biol. Chem. 273:11281-11287(1998) [PubMed] [Europe PMC] [Abstract]
  17. "Mutations in coagulation factors in women with unexplained late fetal loss."N. Engl. J. Med. 343:1015-1018(2000) [PubMed] [Europe PMC] [Abstract]
  18. "Characterization of a novel human protein C inhibitor (PCI) gene transgenic mouse useful for studying the role of PCI in physiological and pathological conditions."J. Thromb. Haemost. 2:949-961(2004) [PubMed] [Europe PMC] [Abstract]
  19. "Human plasma N-glycoproteome analysis by immunoaffinity subtraction, hydrazide chemistry, and mass spectrometry."J. Proteome Res. 4:2070-2080(2005) [PubMed] [Europe PMC] [Abstract]
  20. "Elucidation of N-glycosylation sites on human platelet proteins: a glycoproteomic approach."Mol. Cell. Proteomics 5:226-233(2006) [PubMed] [Europe PMC] [Abstract]
  21. "Phosphoproteome of resting human platelets."J. Proteome Res. 7:526-534(2008) [PubMed] [Europe PMC] [Abstract]
  22. "Quantitative phosphoproteomic analysis of T cell receptor signaling reveals system-wide modulation of protein-protein interactions."Sci. Signal. 2:RA46-RA46(2009) [PubMed] [Europe PMC] [Abstract]
  23. "Crystal structures of the membrane-binding C2 domain of human coagulation factor V."Nature 402:434-439(1999) [PubMed] [Europe PMC] [Abstract]
  24. "A polymorphism in the human coagulation factor V gene."Hum. Mol. Genet. 3:2085-2085(1994) [PubMed] [Europe PMC] [Abstract]
  25. "Mutation in blood coagulation factor V associated with resistance to activated protein C."Nature 369:64-67(1994) [PubMed] [Europe PMC] [Abstract]
  26. "Detection of new polymorphic markers in the factor V gene: association with factor V levels in plasma."Thromb. Haemost. 75:45-48(1996) [PubMed] [Europe PMC] [Abstract]
  27. "Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis."Gut 40:798-800(1997) [PubMed] [Europe PMC] [Abstract]
  28. "A novel mutation of Arg306 of factor V gene in Hong Kong Chinese."Blood 91:1135-1139(1998) [PubMed] [Europe PMC] [Abstract]
  29. "Factor V Cambridge: a new mutation (Arg306-to-Thr) associated with resistance to activated protein C."Blood 91:1140-1144(1998) [PubMed] [Europe PMC] [Abstract]
  30. "Clinical significance of Arg306 mutations of factor V gene."Blood 92:2599-2600(1998) [PubMed] [Europe PMC] [Abstract]
  31. "Characterization of single-nucleotide polymorphisms in coding regions of human genes."Nat. Genet. 22:231-238(1999) [PubMed] [Europe PMC] [Abstract]
  32. ErratumNat. Genet. 23:373-373(1999)
  33. "Combinations of 4 mutations (FV R506Q, FV H1299R, FV Y1702C, PT 20210G/A) affecting the prothrombinase complex in a thrombophilic family."Blood 96:1443-1448(2000) [PubMed] [Europe PMC] [Abstract]
  34. "Five novel mutations in the gene for human blood coagulation factor V associated with type I factor V deficiency."Blood 98:358-367(2001) [PubMed] [Europe PMC] [Abstract]
  35. "Novel factor V C2-domain mutation (R2074H) in two families with factor V deficiency and bleeding."Thromb. Haemost. 87:294-299(2002) [PubMed] [Europe PMC] [Abstract]
  36. "Arg2074Cys missense mutation in the C2 domain of factor V causing moderately severe factor V deficiency: molecular characterization by expression of the recombinant protein."Blood 101:173-177(2003) [PubMed] [Europe PMC] [Abstract]
  37. "Factor V I359T: a novel mutation associated with thrombosis and resistance to activated protein C."Br. J. Haematol. 123:496-501(2003) [PubMed] [Europe PMC] [Abstract]
  38. "Meta-analysis of genetic studies in ischemic stroke: thirty-two genes involving approximately 18,000 cases and 58,000 controls."Arch. Neurol. 61:1652-1661(2004) [PubMed] [Europe PMC] [Abstract]
  39. "Functional characterization of factor V-Ile359Thr: a novel mutation associated with thrombosis."Blood 103:3381-3387(2004) [PubMed] [Europe PMC] [Abstract]
  40. "The consensus coding sequences of human breast and colorectal cancers." Science 314:268-274(2006) [PubMed] [Europe PMC] [Abstract]